-
Mashup Score: 2
For too long, obesity was a subject to avoid in healthcare visits. But now, in just five years, diagnoses of obesity have risen by 50%.
Source: conscienhealth.orgCategories: General Medicine NewsTweet
-
Mashup Score: 6
It seems that presentations at ECO2025 will teach us much about obesity and the burden cancer, liver disease, and a whole lot more.
Source: conscienhealth.orgCategories: General Medicine NewsTweet-
A broad look at the associated benefits of addressing #obesity treatment. @novonordisk and @EliLillyandCo dictate change with robust data supporting comorbidity Rx. Beyond Weight at ECO2025: Cancer, Liver Disease & More - @ConscienHealth https://t.co/LzS0e1JDse
-
-
Mashup Score: 8
Explosive growth in the most severe obesity should put to rest any happy talk about obesity prevalence declining.
Source: conscienhealth.orgCategories: General Medicine NewsTweet-
Explosive Growth in Extremely Severe Obesity (Under the Radar) - @ConscienHealth https://t.co/sl5uXuzhYM
-
-
Mashup Score: 1
With great interest in GLP-1 medicines for weight management, med spas are enjoying amazing growth. What does this tell us about healthcare?
Source: conscienhealth.orgCategories: General Medicine News, General HCPsTweet-
Dysfunctional Healthcare Driving Robust Growth for Med Spas - @ConscienHealth https://t.co/jV8oVqlkYA
-
-
Mashup Score: 4
FDA says the semaglutide shortage is officially over. Is this the end of the line compounding pharmacies, or the start of a new chapter?
Source: conscienhealth.orgCategories: General Medicine News, General HCPsTweet-
The Semaglutide Shortage Is Over. Will Compounding Vanish? - @ConscienHealth https://t.co/3pnBf1EuFm
-
-
Mashup Score: 7
U.S. healthcare is skimming profits from GLP-1s, sowing disparities, and quite possibly dimming the prospects for broad gains in health.
Source: conscienhealth.orgCategories: General Medicine News, General HCPsTweet-
Skimming Profits, Sowing Disparities, and Dimming Prospects - @ConscienHealth https://t.co/SSem8HJvll
-
-
Mashup Score: 13Moving from Hype to Realities in the Obesity Market - ConscienHealth - 5 month(s) ago
For Novo Nordisk and Lilly, 2025 will bring less hype and euphoria and more of the realities of competition in obesity.
Source: conscienhealth.orgCategories: General Medicine News, General HCPsTweet-
Moving from Hype to Realities in the Obesity Market - @ConscienHealth https://t.co/RBb8KsPcl4
-
-
Mashup Score: 24
Why are the disparities in GLP-1 medicines for obesity so great in comparison to their use for diabetes? It’s all about the money.
Source: conscienhealth.orgCategories: General Medicine News, General HCPsTweet-
Disparities in GLP-1 Medicines for Obesity Are Growing Obvious - @ConscienHealth https://t.co/a3TEb24Mc8
-
-
Mashup Score: 8An Easy Win on Obesity for a New Administration - ConscienHealth - 6 month(s) ago
An easy win on obesity is a rare thing. But 70+ health organizations have come together to urge the new administration to take this one.
Source: conscienhealth.orgCategories: General Medicine News, General HCPsTweet-
An Easy Win on Obesity for a New Administration - ConscienHealth https://t.co/fCfQz67thG https://t.co/4g7WawW0NH
-
-
Mashup Score: 22
FDA is in a quandary about compounding of the new obesity drugs, semaglutide and tirzepatide. The nominee to lead FDA has an interest.
Source: conscienhealth.orgCategories: General Medicine News, CardiologistsTweet-
For reference: https://t.co/LBwpy8c01U
-
2019 to 2024: Obesity and Overweight Diagnoses Up by 50% - ConscienHealth https://t.co/HfW9mv6nNz